Litain Yeh, Arthrosi Therapeutics CEO
July 12, 2023 11:14 AM EDT
Financing

San Diego biotech se­cures $75M to ad­vance lead can­di­date

Paul Schloesser

Associate Editor

Arthrosi Ther­a­peu­tics, a biotech com­pa­ny de­vel­op­ing a gout treat­ment, raised a fresh $75 mil­lion through a Se­ries D round.

Ac­cord­ing to a

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

No­vo Nordisk to phase out its pro­duc­tion of hu­man in­sulin pens glob­al­ly

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times